Reprofiled drug targets ancient protozoans: Drug discovery for parasitic diarrheal diseases

Gut Microbes

Volumn 4, Issue 1, 2013, Pages

  Debnath, Anjan ^a   Ndao, Momar ^b   Reed, Sharon L ^c  

^a University of California at San Francisco   (United States)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Auranofin; Cryptosporidium parvum; Diarrheal diseases; Drug discovery; Entamoeba; Giardia; High throughput screen; Orphan drug; Protozoan parasites; Thioredoxin reductase

Indexed keywords

AURANOFIN; METRONIDAZOLE; NITAZOXANIDE; NUCLEOSIDE DIPHOSPHATE KINASE; PAROMOMYCIN; PHENYTOIN; THIOREDOXIN REDUCTASE; ANTIPROTOZOAL AGENT; ENZYME INHIBITOR; ORPHAN DRUG;

AMEBIASIS; ARTICLE; COLITIS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG EFFICACY; DRUG HALF LIFE; DRUG REPOSITIONING; ENTAMOEBA HISTOLYTICA; ENTAMOEBA INVADENS; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GIARDIA LAMBLIA; GIARDIASIS; HIGH THROUGHPUT SCREENING; HUMAN; INTESTINE INFECTION; LIVER AMEBIASIS; MOLECULARLY TARGETED THERAPY; NEGLECTED DISEASE; NONHUMAN; PHENOTYPE; PROTOZOAL INFECTION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; DIARRHEAL DISEASES; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; ENTAMOEBA; GIARDIA; HIGH THROUGHPUT SCREEN; ISOLATION AND PURIFICATION; METHODOLOGY; PROTOZOAN PARASITES; REVIEW;

ANIMALIA; CRYPTOSPORIDIUM PARVUM; ENTAMOEBA; ENTAMOEBA HISTOLYTICA; GIARDIA; GIARDIA INTESTINALIS; PROTOZOA;

AURANOFIN; CRYPTOSPORIDIUM PARVUM; DIARRHEAL DISEASES; DRUG DISCOVERY; ENTAMOEBA; GIARDIA; HIGH THROUGHPUT SCREEN; ORPHAN DRUG; PROTOZOAN PARASITES; THIOREDOXIN REDUCTASE;

ANTIPROTOZOAL AGENTS; AURANOFIN; CRYPTOSPORIDIUM PARVUM; DRUG DISCOVERY; ENTAMOEBA HISTOLYTICA; ENZYME INHIBITORS; GIARDIA LAMBLIA; HIGH-THROUGHPUT SCREENING ASSAYS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84871882795     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Vaidya AB, Ray DK. Amoebiasis: the tropical scourge. Science Today (India) 1982 pp. 21-26.
2. Cox FE. History of human parasitology. Clin Microbiol Rev 2002; 15:595-612; PMID:12364371; http://dx.doi.org/10.1128/CMR.15.4.595-612.2002.
3. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16:713-29; PMID:14557296; http://dx.doi.org/10.1128/CMR.16.4.713-729.2003.
4. Ortega YR, Bonavia D. Cryptosporidium, Giardia, and Cyclospora in ancient Peruvians. J Parasitol 2003; 89:635-6; PMID:12880276; http://dx.doi. org/10.1645/GE-3083RN.
5. Allison MJ, Bergman T, Gerszten E. Further studies on fecal parasites in antiquity. Am J Clin Pathol 1999; 112:605-9; PMID:10549246.
6. WHO/PAHO/UNESCO report. A consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January, 1997. Epidemiol Bull 1997; 18:13-4; PMID:9197085.
7. World Health Organization. The World Health Report 1998: life in the 21st century: a vision for all. Geneva: World Health Organization. 1998.
8. Adam RD. Biology of Giardia lamblia. Clin Microbiol Rev 2001; 14:447-75; PMID:11432808; http://dx.doi.org/10.1128/CMR.14.3.447-475.2001.
9. Wright JM, Dunn LA, Upcroft P, Upcroft JA. Efficacy of antigiardial drugs. Expert Opin Drug Saf 2003; 2:529-41; PMID:14585063; http://dx.doi. org/10.1517/14740338.2.6.529.
10. Fletcher SM, Stark D, Harkness J, Ellis J. Enteric protozoa in the developed world: a public health perspective. Clin Microbiol Rev 2012; 25:420-49; PMID:22763633; http://dx.doi.org/10.1128/CMR.05038-11.
11. Cabada MM, White AC Jr. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis 2010; 23:494-9; PMID:20689422; http://dx.doi.org/10.1097/QCO.0b013e32833de052.
12. Savioli L, Smith H, Thompson A. Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol 2006; 22:203-8; PMID:16545611; http://dx.doi.org/10.1016/j. pt.2006.02.015.
13. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997; 54:679-708; PMID:9360057; http://dx.doi.org/10.2165/00003495-199754050-00003.
14. Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005; 27:1859-84; PMID:16507373; http://dx.doi.org/10.1016/j. clinthera.2005.12.012.
15. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184:381-4; PMID:11443569; http://dx.doi. org/10.1086/322038.
16. Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002; 511:133-44; PMID:12052431; http://dx.doi. org/10.1016/S1383-5742(02)00007-8.
17. Sweetman SC. Martindale: The Complete Drug Reference, 33rd ed. Pharmaceutical Press, London, 2002:594.
18. Wassmann C, Hellberg A, Tannich E, Bruchhaus I. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 1999; 274:26051-6; PMID:10473552; http://dx.doi. org/10.1074/jbc.274.37.26051.
19. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14:150-64; PMID:11148007; http://dx.doi.org/10.1128/CMR.14.1.150-164.2001.
20. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis 2001; 184:103-6; PMID:11398117; http://dx.doi.org/10.1086/321008.
21. Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, Xu F, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis 2009; 3:e478; PMID:19597541; http://dx.doi.org/10.1371/journal. pntd.0000478.
22. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012; 18:956-60; PMID:22610278; http://dx.doi.org/10.1038/nm.2758.
23. von Oettingen J, Nath-Chowdhury M, Ward BJ, Rodloff AC, Arrowood MJ, Ndao M. High-yield amplification of Cryptosporidium parvum in interferon gamma receptor knockout mice. Parasitology 2008; 135:1151-6; PMID:18667105; http://dx.doi. org/10.1017/S0031182008004757.
24. Cai X, Woods KM, Upton SJ, Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob Agents Chemother 2005; 49:4437-42; PMID:16251280; http://dx.doi.org/10.1128/AAC.49.11.4437-4442.2005.
25. Stauffer W, Ravdin JI. Entamoeba histolytica: an update. Curr Opin Infect Dis 2003; 16:479-85; PMID:14502002; http://dx.doi. org/10.1097/00001432-200310000-00016.
26. Stanley SL Jr. Amoebiasis. Lancet 2003; 361:1025-34; PMID:12660071; http://dx.doi.org/10.1016/S0140-6736(03)12830-9.
27. Pritt BS, Clark CG. Amebiasis. Mayo Clin Proc 2008; 83:1154-9, quiz 1159-60; PMID:18828976; http://dx.doi.org/10.4065/83.10.1154.
28. Reynolds JEF. Martindale: The Extra Pharmacopoeia, 30th ed. Pharmaceutical Press, London, 1993:516-21.
29. Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr. Amebiasis. N Engl J Med 2003; 348:1565-73; PMID:12700377; http://dx.doi.org/10.1056/NEJMra022710.
30. Buckner FS, Waters NC, Avery VM. Recent highlights in anti-protozoan drug development and resistance research. Int J Parasitol: Drugs and Drug Res 2012; In press; http://dx.doi.org/10.1016/j.ijpddr. 2012.05.002.
31. Giannini EH, Brewer EJ Jr., Kuzmina N, Shaikov A, Wallin B; The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990; 33:466-76; PMID:2183804; http://dx.doi.org/10.1002/art.1780330402.
32. Gottlieb NL. Pharmacology of auranofin: overview and update. Scand J Rheumatol Suppl 1986; 63:19-28; PMID:3110942.
33. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al.; Rare Diseases Clinical Research Network. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96:20-6; PMID:19013090; http://dx.doi.org/10.1016/j.ymgme.2008.10.003.
34. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 2010; 95:216-28; PMID:20036435; http://dx.doi.org/10.1016/j. healthpol.2009.12.001.
35. Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J 2004; 12:183-200; PMID:16539081.
36. Blower MD, Nachury M, Heald R, Weis KA. A Rae1-containing ribonucleoprotein complex is required for mitotic spindle assembly. Cell 2005; 121:223-34; PMID:15851029; http://dx.doi.org/10.1016/j. cell.2005.02.016.
37. Parks RE Jr., Brown PR, Cheng YC, Agarwal KC, Kong CM, Agarwal RP, et al. Purine metabolism in primitive erythrocytes. Comp Biochem Physiol B 1973; 45:355-64; PMID:4351428; http://dx.doi. org/10.1016/0305-0491(73)90070-9.
38. Simon TM, Kunishima DH, Vibert GJ, Lorber A. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. Cancer Res 1981; 41:94-7; PMID:6778607.
39. Sok J, Calfon M, Lu J, Lichtlen P, Clark SG, Ron D. Arsenite-inducible RNA-associated protein (AIRAP) protects cells from arsenite toxicity. Cell Stress Chaperones 2001; 6:6-15; PMID:11525245; http://dx.doi.org/10.1379/1466-1268(2001)0060006:AIRAPA2.0.CO;2.
40. Rigobello MP, Scutari G, Boscolo R, Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol 2002; 136:1162-8; PMID:12163349; http://dx.doi.org/10.1038/sj.bjp.0704823.
41. Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D, et al. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol In Vitro 2006; 20:882-90; PMID:16510263; http://dx.doi. org/10.1016/j.tiv.2006.01.012.
42. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 2007; 104:12288-93; PMID:17640917; http://dx.doi.org/10.1073/pnas.0701549104.
43. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D, et al. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 2009; 284:28977-85; PMID:19710012; http://dx.doi.org/10.1074/jbc.M109.020701.
44. Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchêne M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol 2007; 5:e211; PMID:17676992; http://dx.doi.org/10.1371/journal.pbio.0050211.
45. Brown DM, Upcroft JA, Edwards MR, Upcroft P. Anaerobic bacterial metabolism in the ancient eukaryote Giardia duodenalis. Int J Parasitol 1998; 28:149-64; PMID:9504342; http://dx.doi. org/10.1016/S0020-7519(97)00172-0.
46. Mondal D, Haque R, Sack RB, Kirkpatrick BD, Petri WA Jr. Attribution of malnutrition to causespecific diarrheal illness: evidence from a prospective study of preschool children in Mirpur, Dhaka, Bangladesh. Am J Trop Med Hyg 2009; 80:824-6; PMID:19407131.
47. Busatti HG, Santos JF, Gomes MA. The old and new therapeutic approaches to the treatment of giardiasis: where are we? Biologics 2009; 3:273-87; PMID:19707415.
48. Cacciò SM, Ryan U. Molecular epidemiology of giardiasis. Mol Biochem Parasitol 2008; 160:75-80; PMID:18501440; http://dx.doi.org/10.1016/j.molbiopara. 2008.04.006.